Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate

• Main Authors: Johanna K Ecke (Author), Luis Del Valle (Author), Amanda Parker Struckhoff (Author), Piotr Waligorski (Author), Krzysztof Reiss (Author), Francesca Peruzzi (Author)
• Format: Book
• Published: International Journal of Veterinary Science and Research - Peertechz Publications, 2015-10-16.
• Subjects: Case Report
• Online Access: Connect to this object online.

<p>Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high...